Search By:
Products
Injury
Topic
Company
Industry
InterMune and Genentech might have fraudulently marketed the drug Actimmune as a treatment for idiopathic pulmonary fibrosis.
Investigation Source
- Nationwide
Investigation Scope
Category Information
Investigation Topics
- Misrepresentation
- Off label promotion of drug
Product or Service
- Actimmune
Injury Type
- Monetary Loss
Investigation Details
Investigation and a pending class action lawsuit against InterMune and Genentech, the marketers and manufacturers of ACTIMMUNE.
The class action lawsuit alleges that Intermune and Genetech committed fraud and deception in the marketing and sale of ACTIMMUNE. Specifically, Intermune deceptively marketed the drug as treatment for idiopathic pulmonary fibrosis (IPF), a deadly disease with no known cause or cure. The lawsuit contends InterMune created and distributed materials that falsely claimed the drug had been shown to extend the lives of IPF patients and could reduce mortality by 70 percent in patients with mild to moderate disease. The disease affects more than 80,000 people in the United States and prohibits the lungs from expanding during breathing, decreasing the availability of oxygen to the bloodstream. InterMune, the pharmaceutical marketing company, recently paid $37 million in restitution to federal and state third-party payors after a federal criminal felony misconduct charge relating to its marketing tactics with ACTIMMUNE media sources reported. This lawsuit is filed on behalf of consumers and private payors who purchased the drug.
If you purchased the drug or made co-payments with your insurance company ACTIMMUNE, you are eligible to join this case.
Do not change medications without first consulting your doctor.
The class action lawsuit alleges that Intermune and Genetech committed fraud and deception in the marketing and sale of ACTIMMUNE. Specifically, Intermune deceptively marketed the drug as treatment for idiopathic pulmonary fibrosis (IPF), a deadly disease with no known cause or cure. The lawsuit contends InterMune created and distributed materials that falsely claimed the drug had been shown to extend the lives of IPF patients and could reduce mortality by 70 percent in patients with mild to moderate disease. The disease affects more than 80,000 people in the United States and prohibits the lungs from expanding during breathing, decreasing the availability of oxygen to the bloodstream. InterMune, the pharmaceutical marketing company, recently paid $37 million in restitution to federal and state third-party payors after a federal criminal felony misconduct charge relating to its marketing tactics with ACTIMMUNE media sources reported. This lawsuit is filed on behalf of consumers and private payors who purchased the drug.
If you purchased the drug or made co-payments with your insurance company ACTIMMUNE, you are eligible to join this case.
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| Intermune, Inc. (ITMN) | InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. |
| Genentech, Inc. (DNA) | Genentech, Inc., together with its subsidiaries, discovers, develops, manufactures, and commercializes pharmaceutical products. |